Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Private Wealth Partners LLC

Private Wealth Partners LLC cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 66.2% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 24,094 shares of the biopharmaceutical company's stock after selling 47,147 shares during the quarter. Private Wealth Partners LLC's holdings in Gilead Sciences were worth $1,653,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Manning & Napier Advisors LLC purchased a new position in shares of Gilead Sciences in the second quarter valued at approximately $25,328,000. Eagle Asset Management Inc. grew its holdings in shares of Gilead Sciences by 23.6% during the fourth quarter. Eagle Asset Management Inc. now owns 317,539 shares of the biopharmaceutical company's stock worth $25,724,000 after buying an additional 60,697 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Gilead Sciences in the first quarter valued at about $462,000. Brookstone Capital Management lifted its stake in shares of Gilead Sciences by 751.1% in the first quarter. Brookstone Capital Management now owns 127,258 shares of the biopharmaceutical company's stock worth $9,322,000 after buying an additional 112,305 shares in the last quarter. Finally, Comerica Bank boosted its position in Gilead Sciences by 10.7% during the fourth quarter. Comerica Bank now owns 329,990 shares of the biopharmaceutical company's stock worth $26,733,000 after acquiring an additional 31,849 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.

Insiders Place Their Bets

In other Gilead Sciences news, insider Johanna Mercier sold 5,490 shares of the firm's stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total value of $406,150.20. Following the completion of the sale, the insider now owns 114,979 shares of the company's stock, valued at $8,506,146.42. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, insider Johanna Mercier sold 5,490 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the sale, the insider now directly owns 114,979 shares in the company, valued at approximately $8,506,146.42. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Merdad Parsey sold 2,000 shares of the company's stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the sale, the insider now owns 96,380 shares in the company, valued at approximately $6,614,559.40. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Stock Performance

Gilead Sciences stock traded up $2.22 during midday trading on Thursday, hitting $83.16. 11,447,700 shares of the company's stock were exchanged, compared to its average volume of 7,172,014. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.95 and a current ratio of 1.14. The stock has a market cap of $103.61 billion, a price-to-earnings ratio of 230.64, a price-to-earnings-growth ratio of 2.73 and a beta of 0.18. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $87.86. The firm's 50 day simple moving average is $74.82 and its 200 day simple moving average is $70.72.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.61 by $0.40. The company had revenue of $6.95 billion for the quarter, compared to the consensus estimate of $6.64 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. Equities research analysts predict that Gilead Sciences, Inc. will post 3.78 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 27th. Shareholders of record on Friday, September 13th will be issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 3.70%. The ex-dividend date is Friday, September 13th. Gilead Sciences's dividend payout ratio is presently 855.56%.

Analyst Ratings Changes

GILD has been the topic of a number of recent research reports. BMO Capital Markets boosted their price objective on Gilead Sciences from $80.00 to $85.00 and gave the stock an "outperform" rating in a research note on Friday, August 9th. Robert W. Baird reaffirmed a "neutral" rating and set a $80.00 target price on shares of Gilead Sciences in a research note on Thursday, June 20th. Piper Sandler reissued an "overweight" rating and issued a $95.00 price target on shares of Gilead Sciences in a research note on Wednesday. Royal Bank of Canada upped their price objective on Gilead Sciences from $72.00 to $74.00 and gave the company a "sector perform" rating in a report on Wednesday, September 4th. Finally, Raymond James raised Gilead Sciences from a "market perform" rating to an "outperform" rating and set a $93.00 target price for the company in a research note on Monday, July 8th. Twelve investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $82.06.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.